- Home
- PCYO vs SGMT Comparison
PCYO vs SGMT Comparison
Compare PCYO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- SGMT
- Stock Information
- Founded
- PCYO 1976
- SGMT 2006
- Country
- PCYO United States
- SGMT United States
- Employees
- PCYO N/A
- SGMT N/A
- Industry
- PCYO Water Supply
- SGMT
- Sector
- PCYO Utilities
- SGMT
- Exchange
- PCYO Nasdaq
- SGMT Nasdaq
- Market Cap
- PCYO 267.7M
- SGMT 238.7M
- IPO Year
- PCYO N/A
- SGMT 2023
- Fundamental
- Price
- PCYO $10.91
- SGMT $8.33
- Analyst Decision
- PCYO
- SGMT Strong Buy
- Analyst Count
- PCYO 0
- SGMT 8
- Target Price
- PCYO N/A
- SGMT $26.88
- AVG Volume (30 Days)
- PCYO 60.2K
- SGMT 641.3K
- Earning Date
- PCYO 11-12-2025
- SGMT 11-12-2025
- Dividend Yield
- PCYO N/A
- SGMT N/A
- EPS Growth
- PCYO 123.89
- SGMT N/A
- EPS
- PCYO 0.56
- SGMT N/A
- Revenue
- PCYO $27,447,000.00
- SGMT N/A
- Revenue This Year
- PCYO N/A
- SGMT N/A
- Revenue Next Year
- PCYO N/A
- SGMT N/A
- P/E Ratio
- PCYO $19.65
- SGMT N/A
- Revenue Growth
- PCYO 40.36
- SGMT N/A
- 52 Week Low
- PCYO $9.65
- SGMT $1.73
- 52 Week High
- PCYO $14.63
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- PCYO 49.06
- SGMT 55.46
- Support Level
- PCYO $10.90
- SGMT $8.02
- Resistance Level
- PCYO $11.11
- SGMT $9.46
- Average True Range (ATR)
- PCYO 0.15
- SGMT 0.66
- MACD
- PCYO -0.02
- SGMT 0.09
- Stochastic Oscillator
- PCYO 41.18
- SGMT 47.68
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.